Concepedia

Maud Jonnaert

MJ

Statistics

Publications

6

Citations

401

H-Index

6

Active since

2005

Affiliations

Novartis (United States)(Current)

Memorial Sloan Kettering Cancer Center

University Hospital Cologne

Seoul National University Hospital

National Taiwan University Hospital

Maud Jonnaert is an author at Novartis (United States) specializing in oncology, radiation oncology, and medicine.

Top concepts

Publications per year

2005–2020

6

Publications

6

Uterine Wnt/β-catenin signaling is required for implantation

Othman A. Mohamed, Maud Jonnaert, Cassandre Labelle‐Dumais et al. · Proceedings of the National Academy of Sciences · 2005 · 221 citations · Full text

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study

Daniel S.W. Tan, Natasha B. Leighl, Gregory J. Riely et al. · The Lancet Respiratory Medicine · 2020 · 84 citations

, , +5

Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.

Wendy Osborne, Maria A. V. Marzolini, Eleni Tholouli et al. · Journal of Clinical Oncology · 2020 · 43 citations

, , +21

Novel imprinted transcripts from the<i>Dlk1-Gtl2</i>intergenic region,<i>Mico1</i>and<i>Mico1os</i>, show circadian oscillations

Stéphane Labialle, Sylvie Croteau, Erin N. McMurray et al. · Epigenetics · 2008 · 21 citations · Full text

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Kirit M. Ardeshna, Maria A. V. Marzolini, Jane E. Norman et al. · Blood · 2019 · 19 citations

1–5 of 6